Among antidepressants for treating juvenile depression, have traditionally played a prominent role tricyclic structure drugs. However, their application in the junior age group is often associated with lack of sufficiently pronounced therapeutic action (often only slightly greater than the placebo effect), at significantly greater than in treating patients with maturity, frequency and severity of side effects.
These deficiencies have virtually no anti-depressants from the group of selective serotonin reuptake inhibitors, like generic Zoloft. Their timoanaleptic impact is associated with the potentiating of serotoninergic brain structures involved in the control of anxiety and depressive affect, impulsive inclinations, sexual and eating behavior, displays of aggression, the regulation of sleep cycles, reduced pain sensitivity, etc.
Continue reading →